Troutman Pepper client Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company, recently announced the initial closing of its Series D financing of up to $37.7 million. The financing was led by Petrichor and included new investor Gore Range Capital. Existing investors Samsara BioCapital, BVF Partners L.P., Agent Capital, Nolan Capital, and BioAdvance also participated in the financing. Read Palvella’s press release about the financing.
Palvella Therapeutics’ vision is to become the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases in indications for which there are no FDA-approved therapies. Proceeds from the financing will be used to advance the development of Palvella’s lead product candidate QTORIN™ rapamycin to treat individuals suffering from Pachyonychia Congenita, Microcystic Lymphatic Malformations, and Gorlin Syndrome.
The Troutman Pepper team advising Palvella Therapeutics in the financing included Chris Miller, Stephen Fox, Roe Granger, and Neil Doogan.
Troutman Pepper is a go-to firm for life sciences transactions with a large, multidisciplinary team with a deep understanding of the space. The firm regularly advises pharmaceutical, biotech, medical device, diagnostics, and other life sciences clients on all types of corporate matters — governance and general corporate advice; M&A transactions; licensing transactions and other complex collaborations; IPOs, follow-on public offerings, PIPE transactions, and other capital markets transactions; seed and later-stage venture capital financings; and much more.
Original source can be found here.